Indolent NHL is a slow-growing form of lymphoma. It encompasses what had been called low-grade NHL and some categories of intermediate-grade NHL. Depending on the type of cancer, patients today often live years without a lot of treatment. The usual strategy had been to wait until symptoms were manifested to a large degree before treatment [...]
Continue reading " Lymphoma Research Foundation Workshop: Indolent Lymphoma "
The practice of treating patients with relatively nonspecific cytotoxic compounds, such as chemotherapy, is now being complemented by a new era of targeted lymphoma drug development. Researchers are now able to identify a wide array of molecular targets and agents. The new agents include several broad classes of drugs that: modulate or change the expression [...]
Continue reading " Lymphoma Research Foundation Workshop: Emerging New Targets "
Standard Therapy At its most fundamental level, cancer has emerged as a disease of genes and DNA, and the entire message can now be interpreted with the aid of sophisticated techniques in molecular and cellular biology.
Continue reading " Lymphoma Research Foundation Workshop: TREATMENT "
OVERVIEW Lymphomas represent about 4% of the new cases of cancer diagnosed in the U.S. each year. They constitute the fifth most common cancer diagnosis and the fifth leading cause of cancer deaths. In fact, although the incidence of most cancers is decreasing, lymphoma is one of only two tumors that are increasing in frequency. [...]
